Propel Bio Partners | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Propel Bio Partners/Activity

Propel Bio Partners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Milestone

Portfolio company EIT Pharma received FDA acceptance of its New Drug Application for lonafarnib to treat chronic hepatitis D.

EIT Pharma

EIT Pharma Propel Bio Partners

prnewswire.comAUG 11, 2026

AUG 11, 2026

Milestone

Portfolio company Achieve Life Sciences received a Complete Response Letter from the FDA for its cytisinicline NDA for smoking cessation.

Achieve Life Sciences

Achieve Life Sciences Propel Bio Partners

reuters.comJUN 22, 2026

JUN 22, 2026

New Fund

Closed a new $100 million fund to back late-stage biotech assets across infectious disease, oncology, and other high-need areas.

$100M fund close

Propel Bio Partners

bizjournals.comMAY 20, 2026

MAY 20, 2026

Investment

Took a post-IPO equity position in Achieve Life Sciences (NASDAQ: ACHV).

Achieve Life Sciences

Achieve Life Sciences Propel Bio Partners

tracxn.comFEB 2024

FEB 2024

Milestone

Portfolio company Inherent Biosciences partnered with Posterity Health to expand access to male reproductive health testing.

Inherent Biosciences

Inherent Biosciences Propel Bio Partners

inherentbio.comJAN 10, 2023

JAN 10, 2023

Investment

Led Inherent Biosciences' Series A funding round for its male reproductive health diagnostics platform.

Inherent Biosciences

Inherent Biosciences Propel Bio Partners

inherentbio.comSEP 7, 2022

SEP 7, 2022

Milestone

Portfolio company Persephone Biosciences enrolled its first participant in the My Baby Biome infant gut health study.

Persephone Biosciences

Persephone Biosciences Propel Bio Partners

businesswire.comAUG 8, 2022

AUG 8, 2022

Investment

Co-led Persephone Biosciences' $15M seed financing round for microbiome-based synbiotic therapeutics.

Persephone Biosciences

Persephone Biosciences Propel Bio Partners

businesswire.comJUL 19, 2022

JUL 19, 2022

Milestone

Portfolio company Persephone Biosciences announced a collaboration with Ginkgo Bioworks to develop novel microbiome-based therapeutics.

Persephone Biosciences

Persephone Biosciences Propel Bio Partners

prnewswire.comAPR 12, 2022

APR 12, 2022

News

Propel Bio Partners launched publicly, backed by Richard Kayne and led by Dr. Leen Kawas.

Propel Bio Partners launch

Propel Bio Partners

wsj.comMAR 18, 2022

MAR 18, 2022